Lundbeck raises financial guidance following strong growth
Denmark-based CNS specialist Lundbeck (LUND: CO) today reported financial results for the first six month of 2024, showing that total revenue rose 10% (+8% at constant exchange rates) to 10,741 million kroner ($1.58 billion), with all regions contributing to growth.
Lundbeck’s shares were up almost 5% at 45.10 kroner by late morning.
Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) increased to 3,365 million kroner (+5% CER) reflecting the strong revenue growth across all strategic brands. Adjusted EBITDA margin reached 31.3% equivalent to a decrease of 2.1 percentage points due to higher raw material and manufacturing costs, increasing share of Vyepti (eptinezumab) on cost of sales as well as unfavorable currency and hedging effects. Adjusted earnings per share (EPS) grew 7%, reaching 2.64 kroner.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze